Sep 11, 2013
Global Green, Inc. Poultry Vaccine for Salmonella to Offer Chemical-Free Solution
Tallahassee, Fla – September 11, 2013 – Global Green, Inc. (OTCBB:GOGC) cites an article in last month’s Washington Post that the U.S. Department of Agriculture (USDA) is reviewing research revealing that new bacteria-killing chemicals used in chicken industry processing plants may be masking the presence of salmonella and other pathogens that remain on the birds that consumers buy, causing food illness.
Global Green has developed a patented vaccine to reduce Salmonella in chicken farming, Salmogenics. It is a safe vaccine that could have significant global impact against this dreaded infectious disease, without dangerous side effects. Salmogenics is currently in the final stage of the USDA approval process.
On September 4, the Company announced the signing of an agreement with Merial Ltd., the Animal Health Division of Sanofi, to conduct an internal evaluation of Global Green’s patented Salmogenics vaccine technology. At the conclusion of the evaluation, Merial has the first option to enter into a license agreement with Global Green for the manufacture, distribution, and sale of the vaccine.
The chemical issue that reportedly currently exists in chicken industry processing plants came to the department’s attention this spring after chemical companies pointed to academic research that shows there could be a problem with chicken farming and told the USDA that further study was needed.
Some experts say the rising tide of chemicals may be causing unanticipated side effects and endangering food safety. Some USDA inspectors believe such chemicals can contribute to a host of healthcare and medical problems, including respiratory ailments and persistent skin rashes.
The World Health Organization (WHO) reports that Salmonellosis is one of the most common and widely distributed infectious diseases, affecting the healthcare of tens of millions of people every year. This is a global health issue.
Dr. Mehran Ghazvini, DC, NMD, Chairman and CEO of biotech company Global Green, Inc., stated “As an infectious disease, Salmonellosis is responsible for a significant burden of disease in the global health arena and is notoriously difficult to control in the poultry farm-to-market cycle. When Salmogenics is used, salmonella contamination is reduced. Not only will consumers have access to a healthier protein source, but the amount of chemicals used in the processing plant will be reduced, providing a healthier work environment for those who work there. This will promote food safety and animal health.”
About Global Green, Inc.
Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company’s flagship product, was developed by Nutritional Health Institute Laboratories, LLC, research affiliate and majority shareholder. For more information, visit www.globalgreeninc.com
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.